ARTICLE | Clinical News
Vandetanib regulatory update
October 25, 2010 7:00 AM UTC
FDA's Oncologic Drugs Advisory Committee will meet on Dec. 2 to discuss an NDA from AstraZeneca for vandetanib to treat advanced medullary thyroid cancer (MTC). The EGFR and VEGF receptor kinase inhi...